Their expression is associated with an overall poor survival probability in ovarian, liver and lung cancer supporting the notion that SRF/IGF2BP1-enhanced gene expression is a conserved driver of oncogenesis that promotes both tumor growth and metastasis (6,26). The gene discussed is SRF; the disease is lung carcinoma.